S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30

Intellia Therapeutics Stock Forecast, Price & News

+6.69 (+8.21%)
(As of 01/24/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
1.70 million shs
Average Volume
1.15 million shs
Market Capitalization
$6.48 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive NTLA News and Ratings via Email

Sign-up to receive the latest news and ratings for Intellia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Intellia Therapeutics logo

About Intellia Therapeutics

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.


Intellia Therapeutics (NASDAQ:NTLA) Trading 3.1% Higher
January 21, 2022 |  americanbankingnews.com
Intellia Therapeutics (NASDAQ:NTLA) Shares Down 5.3%
January 12, 2022 |  americanbankingnews.com
Intellia Therapeutics (NASDAQ:NTLA) Stock Price Up 5.7%
January 7, 2022 |  americanbankingnews.com
What 4 Analyst Ratings Have To Say About Intellia Therapeutics
January 7, 2022 |  markets.businessinsider.com
See More Headlines

Industry, Sector and Symbol

Diagnostic substances
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$57.99 million
Book Value
$8.92 per share


Net Income
$-134.23 million
Net Margins
Pretax Margin




Free Float
Market Cap
$6.48 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.12 out of 5 stars

Medical Sector

512th out of 1,415 stocks

Diagnostic Substances Industry

8th out of 25 stocks

Analyst Opinion: 3.4Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -

Intellia Therapeutics (NASDAQ:NTLA) Frequently Asked Questions

Is Intellia Therapeutics a buy right now?

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last year. There are currently 3 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Intellia Therapeutics stock.
View analyst ratings for Intellia Therapeutics
or view top-rated stocks.

How has Intellia Therapeutics' stock price been impacted by COVID-19?

Intellia Therapeutics' stock was trading at $12.72 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NTLA shares have increased by 593.5% and is now trading at $88.21.
View which stocks have been most impacted by COVID-19

When is Intellia Therapeutics' next earnings date?

Intellia Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Intellia Therapeutics

How were Intellia Therapeutics' earnings last quarter?

Intellia Therapeutics, Inc. (NASDAQ:NTLA) announced its earnings results on Thursday, November, 4th. The company reported ($0.97) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.85) by $0.12. The company earned $7.20 million during the quarter, compared to analyst estimates of $8.66 million. Intellia Therapeutics had a negative net margin of 854.10% and a negative trailing twelve-month return on equity of 34.22%. The company's revenue was down 67.6% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.47) earnings per share.
View Intellia Therapeutics' earnings history

What price target have analysts set for NTLA?

17 Wall Street analysts have issued 12 month target prices for Intellia Therapeutics' stock. Their forecasts range from $85.00 to $252.00. On average, they expect Intellia Therapeutics' stock price to reach $157.56 in the next year. This suggests a possible upside of 78.6% from the stock's current price.
View analysts' price targets for Intellia Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Intellia Therapeutics' key executives?

Intellia Therapeutics' management team includes the following people:

What is John Leonard, M.D.'s approval rating as Intellia Therapeutics' CEO?

12 employees have rated Intellia Therapeutics CEO John Leonard, M.D. on Glassdoor.com. John Leonard, M.D. has an approval rating of 73% among Intellia Therapeutics' employees.

What other stocks do shareholders of Intellia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Square (SQ), Micron Technology (MU), Advanced Micro Devices (AMD), Intel (INTC), Invitae (NVTA) and Cisco Systems (CSCO).

When did Intellia Therapeutics IPO?

(NTLA) raised $85 million in an IPO on Friday, May 6th 2016. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Intellia Therapeutics' stock symbol?

Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."

Who are Intellia Therapeutics' major shareholders?

Intellia Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Russell Investments Group Ltd. (0.10%), Strs Ohio (0.02%), Ipswich Investment Management Co. Inc. (0.01%), Green Alpha Advisors LLC (0.01%), Exchange Traded Concepts LLC (0.00%) and Golden Green Inc. (0.00%). Company insiders that own Intellia Therapeutics stock include Andrew Schiermeier, Caroline Dorsa, David Lebwohl, Glenn Goddard, Jean Francois Formela, John F Crowley, John M Leonard, John M Leonard, Jose E Rivera, Laura Sepp-Lorenzino and Perry A Karsen.
View institutional ownership trends for Intellia Therapeutics

Which major investors are selling Intellia Therapeutics stock?

NTLA stock was sold by a variety of institutional investors in the last quarter, including Aevitas Wealth Management Inc., Strs Ohio, Ipswich Investment Management Co. Inc., and Koshinski Asset Management Inc.. Company insiders that have sold Intellia Therapeutics company stock in the last year include Caroline Dorsa, David Lebwohl, Glenn Goddard, Jean Francois Formela, John F Crowley, John M Leonard, Jose E Rivera, and Laura Sepp-Lorenzino.
View insider buying and selling activity for Intellia Therapeutics
or view top insider-selling stocks.

Which major investors are buying Intellia Therapeutics stock?

NTLA stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Exchange Traded Concepts LLC, Eagle Bay Advisors LLC, Concord Wealth Partners, Golden Green Inc., Lindbrook Capital LLC, Marotta Asset Management, and Newbridge Financial Services Group Inc..
View insider buying and selling activity for Intellia Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Intellia Therapeutics?

Shares of NTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intellia Therapeutics' stock price today?

One share of NTLA stock can currently be purchased for approximately $88.21.

How much money does Intellia Therapeutics make?

Intellia Therapeutics has a market capitalization of $6.48 billion and generates $57.99 million in revenue each year. The company earns $-134.23 million in net income (profit) each year or ($3.36) on an earnings per share basis.

How many employees does Intellia Therapeutics have?

Intellia Therapeutics employs 312 workers across the globe.

What is Intellia Therapeutics' official website?

The official website for Intellia Therapeutics is www.intelliatx.com.

Where are Intellia Therapeutics' headquarters?

Intellia Therapeutics is headquartered at 40 Erie Street Suite 130, Cambridge MA, 02139.

How can I contact Intellia Therapeutics?

Intellia Therapeutics' mailing address is 40 Erie Street Suite 130, Cambridge MA, 02139. The company can be reached via phone at (857) 285-6200 or via email at [email protected].

This page was last updated on 1/25/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.